Comparative Pharmacology
Head-to-head clinical analysis: SITAGLIPTIN METFORMIN HYDROCHLORIDE versus SITAGLIPTIN PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SITAGLIPTIN METFORMIN HYDROCHLORIDE versus SITAGLIPTIN PHOSPHATE.
SITAGLIPTIN; METFORMIN HYDROCHLORIDE vs SITAGLIPTIN PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sitagliptin is a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is a biguanide that decreases hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity via AMP-kinase activation.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing their levels and prolonging their action. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner.
1 tablet orally twice daily; each tablet contains sitagliptin 50 mg and metformin hydrochloride 500 mg, 850 mg, or 1000 mg; maximum dose: sitagliptin 100 mg/day, metformin 2000 mg/day.
100 mg orally once daily.
None Documented
None Documented
Sitagliptin: terminal half-life 12.4 hours (healthy), prolonged in renal impairment (up to 28–39 hours in severe impairment). Metformin: terminal half-life 4–8.7 hours (healthy), prolonged in renal impairment (up to 17.6 hours in moderate impairment).
Terminal elimination half-life: 12.4 hours (range 8–14 hours). Clinically, supports once-daily dosing with gradual onset of DPP-4 inhibition.
Sitagliptin: 79% excreted unchanged in urine via renal tubular secretion and glomerular filtration; 13% metabolized with 4% excreted in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion; <5% in feces.
Renal excretion: ~87% (as unchanged drug in urine); biliary/fecal: ~13% (as metabolites and unchanged drug).
Category A/B
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor